We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Qiming Venture Partners' portfolio company CANbridge Pharmaceuticals (SEHK: 1228), a leading China-based global rare disease-focused biopharmaceutical company, today listed on the main board of Hong Kong, S.A.R., China Stock Exchange.
Biopharmaceutical company CANbridge Pharmaceuticals has signed a licensing agreement with Mirum Pharmaceuticals for the development and commercialisation of maralixibat in Greater China.
Beijing-based CANbridge Life Sciences has received clinical trial application (CTA) approval from the China Food and Drug Administration (CFDA) to conduct clinical trials in China with its drug candidate CAN017.